These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16497224)

  • 1. The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release.
    Varthakavi V; Smith RM; Martin KL; Derdowski A; Lapierre LA; Goldenring JR; Spearman P
    Traffic; 2006 Mar; 7(3):298-307. PubMed ID: 16497224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 particle release mediated by Vpu is distinct from that mediated by p6.
    Schwartz MD; Geraghty RJ; Panganiban AT
    Virology; 1996 Oct; 224(1):302-9. PubMed ID: 8862425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses.
    Bour S; Strebel K
    J Virol; 1996 Dec; 70(12):8285-300. PubMed ID: 8970948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane.
    Neil SJ; Eastman SW; Jouvenet N; Bieniasz PD
    PLoS Pathog; 2006 May; 2(5):e39. PubMed ID: 16699598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Vpu inhibits accumulation of the envelope glycoprotein within clathrin-coated, Gag-containing endosomes.
    Van Damme N; Guatelli J
    Cell Microbiol; 2008 May; 10(5):1040-57. PubMed ID: 18076669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu.
    Varthakavi V; Heimann-Nichols E; Smith RM; Sun Y; Bram RJ; Ali S; Rose J; Ding L; Spearman P
    Nat Med; 2008 Jun; 14(6):641-7. PubMed ID: 18500349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of human immunodeficiency virus type 1 envelope glycoprotein YXXL endocytosis/polarization signal on viral accessory protein functions.
    Cervantes-Acosta G; Lodge R; Lemay G; Cohen EA
    J Hum Virol; 2001; 4(5):249-59. PubMed ID: 11907382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?
    Bour S; Schubert U; Peden K; Strebel K
    J Virol; 1996 Feb; 70(2):820-9. PubMed ID: 8551620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and functional analysis of the membrane-spanning domain of the human immunodeficiency virus type 1 Vpu protein.
    Tiganos E; Friborg J; Allain B; Daniel NG; Yao XJ; Cohen EA
    Virology; 1998 Nov; 251(1):96-107. PubMed ID: 9813206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production.
    Varthakavi V; Smith RM; Bour SP; Strebel K; Spearman P
    Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15154-9. PubMed ID: 14657387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral protein U (Vpu)-mediated enhancement of human immunodeficiency virus type 1 particle release depends on the rate of cellular proliferation.
    Deora A; Ratner L
    J Virol; 2001 Jul; 75(14):6714-8. PubMed ID: 11413341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tethered virions are intermediates in the assembly and release of HIV-1 particles.
    Karetnikov A; Suomalainen M
    Virology; 2010 Nov; 407(2):289-95. PubMed ID: 20850859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulated degradation of the HIV-1 Vpu protein through a betaTrCP-independent pathway limits the release of viral particles.
    Estrabaud E; Le Rouzic E; Lopez-Vergès S; Morel M; Belaïdouni N; Benarous R; Transy C; Berlioz-Torrent C; Margottin-Goguet F
    PLoS Pathog; 2007 Jul; 3(7):e104. PubMed ID: 17676996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human immunodeficiency virus type 1 Vpu protein tethered to the CD4 extracellular domain is localized to the plasma membrane and is biologically active in the secretory pathway of mammalian cells: implications for the mechanisms of Vpu function.
    Raja NU; Jabbar MA
    Virology; 1996 Jun; 220(1):141-51. PubMed ID: 8659106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. M-PMV capsid transport is mediated by Env/Gag interactions at the pericentriolar recycling endosome.
    Sfakianos JN; Hunter E
    Traffic; 2003 Oct; 4(10):671-80. PubMed ID: 12956870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The N-terminal matrix domain of HIV-1 Gag is sufficient but not necessary for viral protein U-mediated enhancement of particle release through a membrane-targeting mechanism.
    Deora A; Spearman P; Ratner L
    Virology; 2000 Apr; 269(2):305-12. PubMed ID: 10753709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 1 VPU protein affects Sindbis virus glycoprotein processing and enhances membrane permeabilization.
    González ME; Carrasco L
    Virology; 2001 Jan; 279(1):201-9. PubMed ID: 11145902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HIV-1 matrix domain of Gag is required for Vpu responsiveness during particle release.
    Lee YH; Schwartz MD; Panganiban AT
    Virology; 1997 Oct; 237(1):46-55. PubMed ID: 9344906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317.
    Bolduan S; Votteler J; Lodermeyer V; Greiner T; Koppensteiner H; Schindler M; Thiel G; Schubert U
    Virology; 2011 Jul; 416(1-2):75-85. PubMed ID: 21601230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rab7A is required for efficient production of infectious HIV-1.
    Caillet M; Janvier K; Pelchen-Matthews A; Delcroix-Genête D; Camus G; Marsh M; Berlioz-Torrent C
    PLoS Pathog; 2011 Nov; 7(11):e1002347. PubMed ID: 22072966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.